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  A 
new study published in   PLoS 
Medicine   by von Seidlein and 
colleagues is a landmark 
in research on shigellosis [1]. von 
Seidlein and colleagues conducted a 
prospective, population-based, multi-
centre study of   Shigella   diarrhoea in 
six Asian countries, producing data on 
disease burden, clinical manifestations, 
and microbiology. The study provides, 
at the scale of a continent, critical 
epidemiological information regarding 
prevention strategies against a largely 
neglected disease that threatens to 
re-emerge due to its highly infectious 
potential and its ability to develop 
resistance to multiple drugs [2].
    The Burden of Diarrhoeal Disease
    There is no sign that the incidence of 
diarrhoeal diseases, which are diseases 
of the poorest, is currently decreasing. 
Morbidity remains high, particularly 
in children younger than the age of 
ﬁ  ve years (3.2 diarrhoea episodes per 
child per year), according to active 
surveillance studies carried out between 
1992 and 2000 [3]. With 2.5 million 
annual deaths, diarrhoea remains a 
leading public health concern, even 
though the attributed mortality has 
steadily declined in endemic areas, 
from 13.6 children per 1,000 per 
year in the period 1954–1979 to 4.9 
children per 1,000 per year in the 
period 1992–2000 [3]. In other words, 
mortality has roughly halved in the 
past 20 years. Better primary care, 
education of mothers, and widespread 
implementation of oral rehydration 
therapy are probably the factors 
that signiﬁ  cantly contributed to the 
decreasing trends in mortality.
    Evaluating the health impact 
of diarrhoea and implementing 
therapeutic and preventive measures 
is a headache for national and 
international health authorities. 
Unlike other infectious diseases, 
such as tuberculosis, HIV/AIDS, and 
malaria, which are all caused by a 
single etiological agent, diarrhoea is 
etiologically diverse. Setting priorities 
for tackling diarrhoeal disease is 
a complex endeavour, and this 
complexity largely accounts for its 
status as a neglected disease. Priorities 
nonetheless emerge, such as the need 
to tackle cholera and cholera-like 
infections caused by enterotoxigenic 
  Escherichia coli  , rotavirus infection, and 
shigellosis. Another priority is vaccine 
development. Rotavirus vaccines are 
currently appearing on the market, and 
promising vaccines against the other 
pathogens that cause diarrhoea are in 
the pipeline [4].
    The time, therefore, has come to 
update epidemiological and disease 
burden data on diarrhoeal diseases, 
particularly for shigellosis. In a 
retrospective, literature-based study on 
shigellosis published in 1999 [5] that has 
become the “gold standard”, projections 
suggested a mean annual morbidity of 
165 million cases and a mean annual 
mortality of 1.1 million cases, 69 percent 
occurring in children younger than ﬁ  ve 
years. But these projections were based 
upon retrospective studies, and so there 
is clearly a need to revisit shigellosis 
epidemiology to see if it is following 
the global trend of diarrhoeal diseases, 
or if it has its own unique evolutionary 
proﬁ  le. 
    More recent epidemiological studies 
carried out in endemic areas raise 
questions about the actual burden of 
the disease and certainly challenge the 
widely accepted idea of a decline in the 
incidence of shigellosis. For instance, 
a recent population-based study 
conducted in Thailand during a period 
of 36 months showed that estimates of 
incidence are 10- to 100-fold higher 
than those found by routine, health 
ministry–based surveillance [6]. Such 
studies conﬁ  rm that shigellosis is 
generally largely underestimated. 
    There are three major reasons for 
this underestimation. First, published 
studies are often based upon passive 
surveillance carried out in medical 
institutions, and, therefore, many 
cases are missed, particularly those 
devoid of dysenteric symptoms that 
do not justify medical attention. 
Whether what counts in public health 
decisions are exhaustive ﬁ  gures on the 
incidence across the entire population 
or simply data on the cases that come 
to medical attention and bear medical 
costs is, of course, an important issue. 
Nevertheless, accurate appreciation of 
circulating strains in the population 
is important for decision makers, 
particularly for a disease that has 
no signiﬁ  cant reservoir other than 
humans, making it a good target for 
eradication by a vaccine. 
    Second,   Shigella   is a very fastidious 
microorganism that “dislikes” transport, 
and for which no enrichment medium 
exists [7]. There is, therefore, a clear 
need for improved, quick, and robust 
methods of straight detection from 
faecal samples. Last but not least, 
signiﬁ  cant numbers of cases occur in 
adults, with a second disease peak after 
the age of 40 years. These cases are not 
necessarily considered in studies that 
are often focused on young children.
    One major issue is at stake here: 
do we still need a vaccine against 
shigellosis [8]? If the morbidity and 
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mortality from shigellosis turn out 
to be declining, one could seriously 
question the relevance of continued 
efforts towards developing a vaccine. 
Such efforts have not, so far, attracted 
signiﬁ  cant interest from vaccine 
companies, and the idea of developing 
such a vaccine may become even less 
appealing if its cost–beneﬁ  t ratio 
were to further decline. On the other 
hand, if the burden of shigellosis is 
  not   falling, epidemiological studies 
would be crucial in deciding which 
type of vaccine should be developed, 
particularly with respect to the number 
of serotypic valences represented 
(protection against   Shigella   infection is 
generally considered serotype speciﬁ  c).
  A  Landmark  Study
    von Seidlein and colleagues’ study of 
the epidemiology and microbiology 
of shigellosis was conducted in study 
sites in three rural or semi-rural areas 
(China, Vietnam, and Thailand) 
and three urban slums (Bangladesh, 
Pakistan, and Indonesia). The authors 
used passive surveillance for case 
detection, which depends on the 
health care–seeking behaviour of 
individual patients, and which risks 
missing a signiﬁ  cant number of cases. 
Nevertheless, the authors included 
more than 600,000 people of all ages, 
which is an impressive achievement. 
Five major points emerged from their 
study.
    First, the researchers found that, 
overall, the incidence of diarrhoeal 
diseases remains high (40 per 1,000 
per year in all age groups, and as high 
as 254 per 1,000 per year in children 
younger than ﬁ  ve years).   Shigella   
infection, diagnosed by classical 
microbiology procedures, accounted 
for ﬁ  ve percent of these diarrhoeal 
episodes, a proportion very similar to 
that found in previous studies [5].
    Second, the researchers also used 
real-time polymerase chain reaction 
(PCR), which can amplify the gene 
coding for the invasion plasmid 
antigen H   (ipaH)  , and which is a more 
sensitive diagnostic technique than 
classical methods. PCR detected   ipaH   
in 33 percent of a sample of culture-
negative stool specimens, suggesting 
that classical methods may miss a 
lot of cases. PCR itself has not yet 
become globally accepted, due to 
the potential for false positives and 
difﬁ  culties of implementation in the 
ﬁ  eld. von Seidlein and colleagues’ 
study emphasizes the urgent need 
to develop robust, sensitive, and 
speciﬁ  c   Shigella   diagnostic tools that 
could detect isolates straight from 
the faecal material. Promising results 
have recently been obtained with 
immunochromatographic techniques 
(that is, dipstick; F. Nato, A. Phalipon, 
P. L. Nguyen Thi, P. Sansonetti, Y. 
Germani, unpublished data).
    Third, in von Seidlein and 
colleagues’ study, mortality associated 
with shigellosis was lower than that 
found in previous epidemiological 
studies, and the current work did 
not demonstrate high numbers of 
late complications in the 90 days of 
follow-up. This trend towards a more 
benign pattern of shigellosis needs 
explanation. The better nutritional 
status of children in economically 
emerging Asian countries is a likely 
possibility, given the signiﬁ  cant 
impact of malnutrition on mortality 
[9]. Other possible explanations are 
quicker access to and improvement of 
primary care, and more extensive use 
of antibiotics. A global change in the 
diverse   Shigella   serotypes is a highly 
unlikely explanation.   Shigella dysenteriae   
type 1, the Shiga bacillus, which has the 
highest attack rate and which is most 
commonly responsible for severe cases 
(due to expression of the Shiga toxin) 
is virtually absent as an epidemic strain 
at the moment in Asia. This absence 
was conﬁ  rmed by the current study.
    Fourth, a major contribution of 
this study is the demonstration of the 
high diversity of serotypes that are 
signiﬁ  cantly represented overall. With 
the exception of Thailand, in which, as 
is already known,   S. sonnei   prevails, in 
other areas the authors found a large 
diversity of serotypes. A serogroup such 
as   S. boydii   that was considered rare and 
limited to the Indian subcontinent has 
now expanded its “zone of activity”. 
This makes the aim of developing 
a serotype-based   Shigella   vaccine a 
difﬁ  cult endeavour, and emphasises 
the need for a switch in paradigm and 
investment in renewed research efforts 
to develop cross-protective vaccine 
candidates. 
    A last, but essential, point is the 
demonstration of the high incidence of 
multiple drug resistance, including all 
ﬁ  rst-line antibiotics (chloramphenicol, 
tetracycline, sulfonamides, ampicillin, 
sulfamethoxazole-trimethoprim, 
and nalidixic acid). This is not a new 
ﬁ  nding, but what is important is the 
demonstration that in some areas 
a signiﬁ  cant percentage of strains 
(about ﬁ  ve percent) is also resistant 
to ﬂ  uoroquinolones, leaving little, if 
any, therapeutic alternative. Large, 
uncontrolled use of antibiotics in 
these areas is likely to provoke a major 
crisis, which may change the proﬁ  le of 
shigellosis once again, but for the worse. 
  Conclusion
    von Seidlein and colleagues found 
that the incidence of shigellosis is 
unchanged, but that there has been a 
trend towards a more benign disease. 
Is this sufﬁ  cient to reconsider the 
relevance of developing a   Shigella   
vaccine? The answer is likely to be no. 
We still do not know the reasons why 
the disease has become less deadly, 
and it is possible that the disease could 
become more deadly in the future, 
especially with the rapid spread of 
multi-drug resistance and the return 
of   S. dysenteriae   type 1. Three-quarters 
of a century ago, Charles Nicolle 
had already warned us against the 
  “génie évolutif”   of infectious diseases. 
Remember also that a “giant” is absent 
from this large-scale study and from 
others: Africa.   
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